Results 81 to 90 of about 514 (108)

Unreported side effect of sincalide.

Radiology, 1994
E B Silberstein, C S Marcus
exaly   +2 more sources

39. Sincalide - the continuing saga

Nuclear Medicine Communications, 2001
S R Hesslewood, L K Harding, A Notghi
exaly   +2 more sources

Utilizing the Cholecystagogue, Ensure Plus, Results in Similar Hepatobiliary Scintigraphy Study Results and Patient Outcomes Status Post Cholecystectomy, in Comparison With Sincalide

Clinical Nuclear Medicine, 2020
Justin Peacock, Kevin P Banks
exaly   +2 more sources

Sincalide-Stimulated Cholescintigraphy

Clinical Nuclear Medicine, 2022
Purpose Current guidelines for sincalide-stimulated cholescintigraphy (SSC) call for a 60-minute sincalide infusion, and a gallbladder ejection fraction (GBEF) ≥38% is considered normal. In this retrospective study, we hypothesize that most patients reach a normal GBEF by 30 minutes. Methods
Anil, Vasireddi, Nghi C, Nguyen
openaire   +2 more sources

Use of CCK agonist sincalide for diagnostic and therapeutic ERCP

Gastrointestinal Endoscopy, 1996
Allan P Weston
exaly   +2 more sources

Studies of gallbladder contraction using intramuscular sincalide.

Radiology, 1983
Intramuscular sincalide (the carboxy terminal octapeptide of cholecystokinin) was evaluated as an agent for producing gallbladder contraction. Following oral cholecystography 35 patients received intramuscular sincalide in one of two dosages, 18 patients received intravenous sincalide, and six patients were given intramuscular placebo.
C J, Rosenquist, T C, Barcia
openaire   +2 more sources

Normal Values for Sincalide Cholescintigraphy: Comparison of Two Methods

Radiology, 2001
To establish normal gallbladder ejection fraction (GBEF) values for two sincalide (cholecystokinin [CCK]) infusion dose rates, 0.01 microg per kilogram of body weight infused for 3 minutes and 0.01 microg/kg infused for 60 minutes.Twenty healthy subjects were examined.
H A, Ziessman, L R, Muenz, A K, Agarwal, A A, ZaZa   +3 more
openaire   +2 more sources

Treatment of vincristine-induced ileus with sincalide, a cholecystokinin analog

Cancer Chemotherapy and Pharmacology, 1982
Sincalide, a synthetic analog of cholecystokinin capable of stimulating bowel motility, has been administered to 12 patients with symptoms and signs of vincristine-induced ileus. Patients were given intravenous infusions of sincalide 0.01 microgram/kg/h over 2-24 h (mean, 8 h) for 1-12 days (mean, 5 days), usually until all evidence of ileus had ...
D V, Jackson, W C, Wu, C L, Spurr
openaire   +2 more sources

Practical Hepatobiliary Imaging Using Pretreatment with Sincalide in 139 Hepatobiliary Studies

Clinical Nuclear Medicine, 1985
Hepatobiliary studies were performed over a three-year period on 139 patients suspected of having cystic duct obstruction. Each patient was infused intravenously with sincalide, a C-terminal octapeptide of CCK, 15 minutes prior to the administration of the hepatobiliary imaging agent Tc-99m paraisopropyl iminodiacetic acid (PIPIDA).
F K, Patterson, J W, Kam
openaire   +2 more sources

Hemobilia Presenting as Intermittent Gastrointestinal Hemorrhage With Sincalide Confirmation A Case Report

Clinical Nuclear Medicine, 1995
An 82-year-old man had his third episode of melanotic stool. Two previous workups had failed to localize the source of bleeding. A Tc-99m labeled RBC scan visualized the gallbladder early in the study. Administration of sincalide visually decreased the activity, confirming gallbladder activity.
M E, Spieth, C C, Hou, P D, Ewing, D K, Price, R L, Kimura, T K, Kawada   +5 more
openaire   +2 more sources